Suppr超能文献

细胞核和细胞质中高表达的CD133预示非小细胞肺癌预后不良。

High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.

作者信息

Huang Minjie, Zhu Huijun, Feng Jian, Ni Songshi, Huang Jianfei

机构信息

Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.

Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China.

出版信息

Dis Markers. 2015;2015:986095. doi: 10.1155/2015/986095. Epub 2015 Jan 18.

Abstract

OBJECTIVE

The aim of this study was to investigate the expression of Prominin-1 (CD133) in cancer cells and its potential value as a prognostic indicator of survival in patients with non-small cell lung cancer (NSCLC).

METHODS

Cancerous tissues and matched normal tissues adjacent to the carcinoma from 239 NSCLC patients were obtained immediately after surgery. Immunohistochemistry of tissue microarrays was used to characterize the expression of CD133 in NSCLC and adjacent tissues. The correlation of CD133 expression with clinical characteristics and prognosis was determined by statistical analysis.

RESULTS

CD133 protein expression levels in both the cytoplasm and nucleus were significantly higher in NSCLC tissues compared with corresponding peritumoral tissue (P < 0.05). CD133 expression in the nucleus of NSCLC cells was related to tumor diameter (P = 0.027), tumor differentiation (P < 0.001), and TNM stage (P = 0.007). Kaplan-Meier survival and Cox regression analyses revealed that high CD133 expression in the nucleus was an independent predictor of poor prognosis of NSCLC, as was high cytoplasmic CD133 expression (P < 0.001).

CONCLUSION

Our findings provide the first evidence that high expression of CD133 in both the nucleus and cytoplasm is associated with poor prognosis in NSCLC.

摘要

目的

本研究旨在调查Prominin-1(CD133)在癌细胞中的表达及其作为非小细胞肺癌(NSCLC)患者生存预后指标的潜在价值。

方法

239例NSCLC患者术后立即获取癌组织及与之匹配的癌旁正常组织。采用组织芯片免疫组化法检测NSCLC组织及癌旁组织中CD133的表达情况。通过统计学分析确定CD133表达与临床特征及预后的相关性。

结果

与相应癌旁组织相比,NSCLC组织中细胞质和细胞核内的CD133蛋白表达水平均显著升高(P < 0.05)。NSCLC细胞核内CD133表达与肿瘤直径(P = 0.027)、肿瘤分化程度(P < 0.001)及TNM分期(P = 0.007)相关。Kaplan-Meier生存分析和Cox回归分析显示,细胞核内高表达CD133是NSCLC预后不良的独立预测指标,细胞质内高表达CD133亦是如此(P < 0.001)。

结论

我们的研究结果首次证明,细胞核和细胞质内CD133高表达均与NSCLC预后不良相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6758/4323063/b88cc388f05e/DM2015-986095.001.jpg

相似文献

1
High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
Dis Markers. 2015;2015:986095. doi: 10.1155/2015/986095. Epub 2015 Jan 18.
2
The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4.
6
Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.
Cancer Invest. 2015;33(7):294-302. doi: 10.3109/07357907.2015.1034869. Epub 2015 Jun 5.

引用本文的文献

1
Immunohistochemistry expression of stem cell markers SOX2, OCT4, CD133 in different grades of meningiomas and correlation with Ki 67 index.
Med J Armed Forces India. 2024 Nov-Dec;80(6):687-694. doi: 10.1016/j.mjafi.2023.09.012. Epub 2023 Nov 11.
2
Correlation of CD 133 Biomarker with Outcomes and Therapy Response in Advanced-Stage Non-Small Cell Lung Carcinoma.
Asian Pac J Cancer Prev. 2024 Sep 1;25(9):3315-3325. doi: 10.31557/APJCP.2024.25.9.3315.
3
6
Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.
Int J Mol Sci. 2023 Dec 12;24(24):17398. doi: 10.3390/ijms242417398.
7
Functional Roles of CD133: More than Stemness Associated Factor Regulated by the Microenvironment.
Stem Cell Rev Rep. 2024 Jan;20(1):25-51. doi: 10.1007/s12015-023-10647-6. Epub 2023 Nov 3.
8
An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC).
Biomedicines. 2023 Sep 19;11(9):2576. doi: 10.3390/biomedicines11092576.
9
Metabolic Reprogramming and Lipophagy Mediates Survival of Ascites Derived Metastatic Ovarian Cancer Cells.
Asian Pac J Cancer Prev. 2022 May 1;23(5):1699-1709. doi: 10.31557/APJCP.2022.23.5.1699.
10
Potential of Stem Cells and CART as a Potential Polytherapy for Small Cell Lung Cancer.
Front Cell Dev Biol. 2021 Dec 3;9:778020. doi: 10.3389/fcell.2021.778020. eCollection 2021.

本文引用的文献

1
Protein kinase inhibitors to treat non-small-cell lung cancer.
Expert Opin Pharmacother. 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. Epub 2014 Apr 19.
2
Clinicopathological significance of CD133 in lung cancer: A meta-analysis.
Mol Clin Oncol. 2014 Jan;2(1):111-115. doi: 10.3892/mco.2013.195. Epub 2013 Sep 30.
3
Lung cancer stem cells and implications for future therapeutics.
Cell Biochem Biophys. 2014 Jul;69(3):389-98. doi: 10.1007/s12013-014-9844-4.
4
Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. doi: 10.1016/j.bbrc.2014.01.164. Epub 2014 Feb 3.
5
Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: a case report.
Tumori. 2013 Sep-Oct;99(5):e245-50. doi: 10.1177/030089161309900523.
6
Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer.
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2887-95. eCollection 2013.
8
CD24+/CD38- as new prognostic marker for non-small cell lung cancer.
Multidiscip Respir Med. 2013 Oct 5;8(1):65. doi: 10.1186/2049-6958-8-65.
9
The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Mol Med Rep. 2013 Nov;8(5):1511-8. doi: 10.3892/mmr.2013.1667. Epub 2013 Sep 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验